CO2018012941A2 - Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos - Google Patents

Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos

Info

Publication number
CO2018012941A2
CO2018012941A2 CONC2018/0012941A CO2018012941A CO2018012941A2 CO 2018012941 A2 CO2018012941 A2 CO 2018012941A2 CO 2018012941 A CO2018012941 A CO 2018012941A CO 2018012941 A2 CO2018012941 A2 CO 2018012941A2
Authority
CO
Colombia
Prior art keywords
benzoimidazol
diethylamino
acrylamide
hydroxy
butyl
Prior art date
Application number
CONC2018/0012941A
Other languages
English (en)
Spanish (es)
Inventor
David Duncan
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of CO2018012941A2 publication Critical patent/CO2018012941A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14Radicals substituted by nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08Radicals containing only hydrogen and carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2018/0012941A 2016-05-02 2018-11-29 Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos CO2018012941A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662330673P 2016-05-02 2016-05-02
PCT/US2017/030414 WO2017192451A1 (en) 2016-05-02 2017-05-01 Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof

Publications (1)

Publication Number Publication Date
CO2018012941A2 true CO2018012941A2 (es) 2018-12-28

Family

ID=60203321

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0012941A CO2018012941A2 (es) 2016-05-02 2018-11-29 Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos

Country Status (20)

Country Link
US (2) US10626092B2 (cg-RX-API-DMAC7.html)
EP (2) EP3939966A1 (cg-RX-API-DMAC7.html)
JP (1) JP2019514905A (cg-RX-API-DMAC7.html)
KR (1) KR20190005904A (cg-RX-API-DMAC7.html)
CN (1) CN109414425A (cg-RX-API-DMAC7.html)
AR (1) AR108257A1 (cg-RX-API-DMAC7.html)
AU (1) AU2017261218A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018072439A2 (cg-RX-API-DMAC7.html)
CA (1) CA3022011A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018003109A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018012941A2 (cg-RX-API-DMAC7.html)
EA (1) EA201892341A1 (cg-RX-API-DMAC7.html)
ES (1) ES2886495T3 (cg-RX-API-DMAC7.html)
IL (1) IL262578A (cg-RX-API-DMAC7.html)
MA (1) MA44880A (cg-RX-API-DMAC7.html)
MX (1) MX382095B (cg-RX-API-DMAC7.html)
PH (1) PH12018502296B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201809471UA (cg-RX-API-DMAC7.html)
TW (1) TW201741286A (cg-RX-API-DMAC7.html)
WO (1) WO2017192451A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018157741A1 (zh) * 2017-02-28 2018-09-07 苏州科睿思制药有限公司 Sb-939的盐的晶型及其制备方法和用途
EP3728205A1 (en) 2017-12-19 2020-10-28 Assia Chemical Industries Ltd Crystalline polymorphs of pracinostat and pracinostat salts
WO2019149262A1 (zh) * 2018-02-05 2019-08-08 苏州科睿思制药有限公司 Sb-939的晶型及其制备方法和用途
WO2021217180A1 (en) * 2020-04-22 2021-10-28 Johnson Matthey Public Limited Company Novel forms of pracinostat dihydrochloride

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2291749A1 (fr) 1974-11-20 1976-06-18 Delalande Sa Nouveaux benzimidazoles acetiques, leur procede de preparation et leur application en therapeutique
DE69329856D1 (de) 1992-05-20 2001-02-15 Merck & Co Inc Ester derivate von 4-aza-steroiden
SE9804212D0 (sv) 1998-12-04 1998-12-04 Astra Pharma Prod Compounds
IL144214A0 (en) 1999-01-13 2002-05-23 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
US6329380B1 (en) 1999-06-30 2001-12-11 Merck & Co., Inc. SRC kinase inhibitor compounds
WO2001000213A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
PL352835A1 (en) 1999-07-16 2003-09-08 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
HUP0202180A3 (en) 1999-07-16 2004-10-28 Warner Lambert Co Method for treating chronic pain using mek inhibitors
GB9919558D0 (en) 1999-08-18 1999-10-20 Hoechst Schering Agrevo Gmbh Fungicidal compounds
EP1748046A3 (en) 1999-11-23 2007-08-22 Methylgene, Inc. Inhibitors of histone deacetylase
NZ514403A (en) 1999-12-27 2002-10-25 Japan Tobacco Inc Fused-ring compounds and use thereof as drugs
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
HUP0400651A2 (hu) 2000-11-07 2004-06-28 Bristol-Myers Squibb Company Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
CA2450555A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
EP1472216A2 (en) 2002-02-07 2004-11-03 Axys Pharmaceuticals Novel bicyclic hydroxamates as inhibitors of histone deacetylase
TWI350285B (en) 2002-03-13 2011-10-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
CA2478534A1 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as mek inhibitors
CN1659161A (zh) 2002-04-16 2005-08-24 帝人株式会社 具有ccr3拮抗作用的哌啶衍生物
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
WO2004078682A2 (en) 2003-03-05 2004-09-16 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
PT1673349E (pt) 2003-09-22 2010-09-28 S Bio Pte Ltd Derivados benzimidazole: preparação e aplicações farmacêuticas
WO2005065681A1 (en) 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
US20050137234A1 (en) 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2006101456A1 (en) 2005-03-21 2006-09-28 S*Bio Pte Ltd Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors
AU2006201177B2 (en) * 2005-09-08 2012-06-14 Mei Pharma, Inc. Heterocyclic compounds
AR055364A1 (es) 2005-09-08 2007-08-22 S Bio Pte Ltd Derivados de benzimidazol
ES2703592T3 (es) * 2007-03-07 2019-03-11 Mei Pharma Inc Combinación de agente anticancerígeno de bencimidazol y un segundo agente anticancerígeno
CA2927565C (en) 2012-10-30 2021-05-18 Mei Pharma, Inc. Combination therapies

Also Published As

Publication number Publication date
PH12018502296A1 (en) 2019-07-08
WO2017192451A1 (en) 2017-11-09
AR108257A1 (es) 2018-08-01
EP3452035A4 (en) 2019-09-25
US20200317621A1 (en) 2020-10-08
EA201892341A1 (ru) 2019-05-31
US20190152923A1 (en) 2019-05-23
MX2018013349A (es) 2019-02-20
KR20190005904A (ko) 2019-01-16
EP3452035B1 (en) 2021-07-07
US10626092B2 (en) 2020-04-21
PH12018502296B1 (en) 2022-04-06
EP3452035A1 (en) 2019-03-13
JP2019514905A (ja) 2019-06-06
AU2017261218A1 (en) 2018-11-29
MA44880A (fr) 2021-03-17
ES2886495T3 (es) 2021-12-20
SG11201809471UA (en) 2018-11-29
CL2018003109A1 (es) 2019-04-26
BR112018072439A2 (pt) 2019-02-19
EP3939966A1 (en) 2022-01-19
TW201741286A (zh) 2017-12-01
IL262578A (en) 2018-12-31
CA3022011A1 (en) 2017-11-09
CN109414425A (zh) 2019-03-01
MX382095B (es) 2025-03-13

Similar Documents

Publication Publication Date Title
CO2019008783A2 (es) Compuestos dinucleotidos ciclicos para el tratamiento del cancer
CL2019001744A1 (es) Derivados de benzoxazol como inmunomoduladores.
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
CO2018005954A2 (es) Compuestos heteroaromáticos como inhibidores de btk
ECSP17073743A (es) Moduladores de k-ras
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CO2017001884A2 (es) Polimorfos de selinexor
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
ECSP18012103A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
DOP2018000040A (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
CR20170005A (es) Derivados de insoindolina
HUE051296T2 (hu) Benzoxazinon-származékok bõrbetegségek kezelésére
CL2018001085A1 (es) Derivados de indolin-2-ona
CO2018012941A2 (es) Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos
UY36221A (es) Derivados de isoindolinona
MX2018008895A (es) Compuestos de 2-oxindol.
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
IL262801A (en) 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers
MX2017008373A (es) Compuestos, composiciones y metodos.
LT3519050T (lt) Kompozicijos, skirtos oftalmologinių būklių gydymui